Australian Public Assessment Report for Nivolumab

Hodgkin lymphoma is considered to be a suitable target for PD-1 immune checkpoint inhibitors due to the extensive, but ineffective inflammatory and immune cell infiltrate, that surrounds Reed-Sternberg (R-S) cells within the tumours and due to high levels of expression of PD-L1 ligand by R-S cells. ................
................